EURAZEO_REGISTRATION_DOCUMENT_2017

PRESENTATION OF THE GROUP

Joint interview

1

Business was very active in 2017: What were the most significant transactions?

Aside from this steady business, there were also strategic developments: partnershipwith Rhône, alliance with Idinvest, doubling your assets, new activity segments: Was 2017 really a year of transformation for Eurazeo? R VM : The major strategic advances that we carried out in 2017 perfectly illustrate the decisions made in recent years to accelerate the development of new business lines, new strategies and, specifically, third-party management. Through the partnership with Rhône and the alliance with Idinvest, we have been riding a wave that began some time ago: in 2006, we created the first fund, Eurazeo Partners, then in 2014, we launched Eurazeo PME II, then Eurazeo Capital II and finally Eurazeo PME III, in June. Because of our partnership with Rhône, a reputable transatlantic investment company, we have been able to bolster our unique business model based on the synergies •/••

France. Eurazeo Capital acquired the Spanish producer of fragrances and flavors, Iberchem. We also finalized the purchase of the iconic Mondelez confectionery and chocolate brands using top-flight “Made in France” companies to create Carambar & Co, Capital completed its first two U.S. investments in Trader Interactive and WorldStrides. Only six months after its creation, Eurazeo Brands finally completed its first investment in NEST Fragrances, a home fragrances company and leader in the United States. Q Virginie Morgon : Key transactions were also carried out within Eurazeo Capital’s portfolio companies with our financial backing. Specifically, the acquisition by Elis of its British competitor Berendsen in June, positioned Elis as the pan- European textile, hygiene and facility services leader and the acquisition of Planet Payment by Fintrax. a French confectionery and chocolate champion. Eurazeo

R Patrick Sayer : 2017 was indeed an exceptional year for Eurazeo. It was one of the busiest in the company’s history in terms of both investments and divestments. Our five investment teams were highly active, which illustrates the diversity of Eurazeo’s expertise and the relevance of its choices. Eurazeo PME acquired a majority interest in the innovative company, Smile, a leading integrator and outsourcer of open source solutions and added to its medical expertise by acquiring Intech’Medical, a world- leading in the manufacturing of surgical instruments for the orthopedic industry. Eurazeo Croissance acquired a minority interest in Doctolib, which is spearheading the healthcare sector’s digital transformation. Eurazeo Patrimoine invested in C2S Group, the eighth largest private clinic operator in

Eurazeo

2017 Registration document

7